Tango Therapeutics (TNGX) Current Deferred Revenue (2020 - 2025)

Tango Therapeutics' Current Deferred Revenue history runs 6 years deep, the most recent figure standing at $23.4 million for Q2 2025.

• In Q2 2025, Current Deferred Revenue fell 1.24% year-over-year to $23.4 million; the TTM figure through Jun 2025 stood at $23.4 million (down 1.24% YoY), while the FY2024 annual figure was $17.6 million, down 31.37% from the prior year.
• Current Deferred Revenue was $23.4 million for Q2 2025 at Tango Therapeutics, up from $19.5 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $34.0 million in Q1 2023 to a low of $15.6 million in Q3 2024.
• Historically, Current Deferred Revenue has averaged $25.7 million across 5 years, with a median of $25.8 million in 2021.
• The sharpest annual moves came in 2023 and 2024: Current Deferred Revenue soared 35.91% in 2023, then slumped 42.37% in 2024.
• A 5-year view of Current Deferred Revenue shows it stood at $26.0 million in 2021, then gained by 22.17% to $31.8 million in 2022, then decreased by 19.26% to $25.7 million in 2023, then slumped by 31.37% to $17.6 million in 2024, then jumped by 32.67% to $23.4 million in 2025.
• The last three Current Deferred Revenue figures came in at $23.4 million (Q2 2025), $19.5 million (Q1 2025), and $17.6 million (Q4 2024), per Business Quant data.